, /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against LifeMD, Inc. (NASDAQ: LFMD) ("LifeMD" or the "Company") on behalf of investors who purchased or acquired shares during the period from May 7, 2025 through August 5, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired LifeMD securities during the Class Period may, no later than October 27, 2025, seek to be appointed as a lead plaintiff representative of the class. To lea ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [3]. Company Overview - LifeMD, Inc. is headquartered in New York and specializes in providing virtual medical services and prescription delivery [2]. Lawsuit Details - The lawsuit covers investors who purchased LifeMD shares from May 7, 2025, to August 5, 2025, and claims that the company failed to disclose rising customer acquisition costs associated with its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. - The complaint asserts that LifeMD's statements during the class period were materially false and misleading, lacking a reasonable basis [3]. Investor Information - Investors who acquired LifeMD securities during the class period have until October 27, 2025, to seek appointment as lead plaintiff representatives [2].